Lindsey Shapiro, PhD, science writer —

Doctors should take care not to oversimplify when talking to patients about treatment decisions for chronic illnesses, according to patients, caregivers, and physicians interviewed for a study focusing on CFTR modulator therapy for cystic fibrosis (CF). It’s also important to have “compassionate conversations” with patients who aren’t eligible…

Gut bacteria called Bacteroides had anti-inflammatory effects in the blood and airways of a mouse model of cystic fibrosis (CF) via its production of an immune-modulating metabolite called propionate, a study finds. The findings add to evidence of a so-called gut-lung axis, where microbes in the gut can influence…

Stopping treatment with inhaled supportive therapies hypertonic saline (HS) or Pulmozyme (dornase alfa) didn’t negatively affect airway mucus clearance among cystic fibrosis (CF) patients with mild lung disease who were being also treated with Trikafta (elexacaftor/tezacaftor/ivacaftor), a report suggests. Indeed, the findings from the six-week study…

ReCode Therapeutics has launched a Phase 1 clinical trial to evaluate the safety of RCT2100, its investigational genetic medicine for  cystic fibrosis (CF), in healthy volunteers and the first group of participants has been dosed. RCT2100 is being developed for CF patients with class I mutations in the…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), sold in the U.S. as Trikafta, reduced signs of sinus disease, as seen on MRI scans, among children with cystic fibrosis (CF), according to new research from Germany. Improvements were seen on the children’s imaging scans regardless of whether they had never before used…

Adults with cystic fibrosis (CF) make as much use of most routine preventive healthcare services as adults in the general population, and in some cases more than they do, according to a recent analysis of U.S. insurance claims data. This services — of growing importance as CFTR modulator…

The diversity and relative abundance of microbes in the lungs — or the lung microbiome — was generally stable over an eight-month period in people with cystic fibrosis (CF), regardless of whether they had experienced a pulmonary exacerbation, according to a recent study. In the short term, using…

A high burden of infection-causing bacteria persisted in the lungs of people with cystic fibrosis (CF) who were treated with Trikafta (elexacaftor/tezacaftor/ivacaftor) in a recent study, despite an increase in the overall diversity of microbes and improvements in lung function being seen. The changing dynamics of this microbial…

African American cystic fibrosis (CF) patients described, in a new interview study, the lifetime of challenges they face in living with a disease often misconstrued as one that only affects white people. A lack of representation and cultural insensitivity from healthcare teams, mental health concerns, and an inability to…

Researchers have developed a lab model of a cystic fibrosis (CF) lung infection that can help inform how antibiotic-resistant infections arise and to test antimicrobial treatment candidates. A human phlegm-like substance was generated where multiple types of microbes were able to grow into three-dimensional (3D) biofilms, the protective clusters…